Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting 8-12-2025, 05:30

British AI Firm, Quantexa, Commits to Over £200M in AI Research and Development Investment by 2027 10-07-2023, 06:01

SHARED INTEREST PRESENTS A VIRTUAL CONVERSATION ON SOCIAL 8-03-2023, 22:27